King M - Search Results

1

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR; PEARL-III Study; PEARL-IV Study. Ferenci P, et al. Among authors: king m. N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4. N Engl J Med. 2014. PMID: 24795200 Free article. Clinical Trial.

2

Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.

Alqahtani S, Ozaras R, Isakov V, Wyles D, Ferenci P, Feld JJ, Calinas F, Gschwantler M, Gane E, Crawford D, Jacobson IM, Dumas EO, King M, Sulkowski M. Alqahtani S, et al. Among authors: king m. J Viral Hepat. 2017 Apr;24(4):280-286. doi: 10.1111/jvh.12641. Epub 2016 Dec 9. J Viral Hepat. 2017. PMID: 27935166

3

Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.

Lalezari J, Sullivan JG, Varunok P, Galen E, Kowdley KV, Rustgi V, Aguilar H, Felizarta F, McGovern B, King M, Polepally AR, Cohen DE. Lalezari J, et al. Among authors: king m. J Hepatol. 2015 Aug;63(2):364-9. doi: 10.1016/j.jhep.2015.03.029. Epub 2015 Apr 1. J Hepatol. 2015. PMID: 25839406 Free article. Clinical Trial.

4

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E; M98-863 Study Team. Walmsley S, et al. Among authors: king m. N Engl J Med. 2002 Jun 27;346(26):2039-46. doi: 10.1056/NEJMoa012354. N Engl J Med. 2002. PMID: 12087139 Free article. Clinical Trial.

5

A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.

Johnson MA, Gathe JC Jr, Podzamczer D, Molina JM, Naylor CT, Chiu YL, King MS, Podsadecki TJ, Hanna GJ, Brun SC. Johnson MA, et al. J Acquir Immune Defic Syndr. 2006 Oct 1;43(2):153-60. doi: 10.1097/01.qai.0000242449.67155.1a. J Acquir Immune Defic Syndr. 2006. PMID: 16951643 Clinical Trial.

6

A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.

Molina JM, Podsadecki TJ, Johnson MA, Wilkin A, Domingo P, Myers R, Hairrell JM, Rode RA, King MS, Hanna GJ. Molina JM, et al. Among authors: king ms. AIDS Res Hum Retroviruses. 2007 Dec;23(12):1505-14. doi: 10.1089/aid.2007.0107. AIDS Res Hum Retroviruses. 2007. PMID: 18160008 Clinical Trial.

7

Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.

Eron JJ, Feinberg J, Kessler HA, Horowitz HW, Witt MD, Carpio FF, Wheeler DA, Ruane P, Mildvan D, Yangco BG, Bertz R, Bernstein B, King MS, Sun E. Eron JJ, et al. J Infect Dis. 2004 Jan 15;189(2):265-72. doi: 10.1086/380799. Epub 2004 Jan 7. J Infect Dis. 2004. PMID: 14722892 Clinical Trial.

8

Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.

Campo RE, Da Silva BA, Cotte L, Gathe JC, Gazzard B, Hicks CB, Klein CE, Chiu YL, King MS, Bernstein BM. Campo RE, et al. Among authors: king ms. AIDS Res Hum Retroviruses. 2009 Mar;25(3):269-75. doi: 10.1089/aid.2008.0217. AIDS Res Hum Retroviruses. 2009. PMID: 19292590 Clinical Trial.

9

Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.

Mo H, King MS, King K, Molla A, Brun S, Kempf DJ. Mo H, et al. J Virol. 2005 Mar;79(6):3329-38. doi: 10.1128/JVI.79.6.3329-3338.2005. J Virol. 2005. PMID: 15731227 Free PMC article. Clinical Trial.

10

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.

Hicks C, King MS, Gulick RM, White AC Jr, Eron JJ Jr, Kessler HA, Benson C, King KR, Murphy RL, Brun SC. Hicks C, et al. Among authors: king kr, king ms. AIDS. 2004 Mar 26;18(5):775-9. doi: 10.1097/00002030-200403260-00008. AIDS. 2004. PMID: 15075512 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,863 results

Search Page